The Symptoms Of Multiple Sclerosis Blog

Information and Resources on Multiple Sclerosis and its signs and symptoms!
English flagItalian flagKorean flagChinese (Simplified) flagPortuguese flagGerman flagFrench flagSpanish flagJapanese flagArabic flagRussian flagGreek flagDutch flagBulgarian flagCzech flagCroat flagDanish flagFinnish flagHindi flagPolish flagRumanian flagSwedish flagNorwegian flag
By N2H

BG-12, Biogen Idec’s Novel Oral Compound Shown To Significantly Reduced Brain Lesions In Patients With Multiple Sclerosis October 27, 2008

Filed under: MS — The Symptoms Of Multiple Sclerosis Blog @ 7:00 am

Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company’s novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • StumbleUpon
  • Technorati


add to del.icio.usPrint This Post Print This Post

Leave a Reply